Omniscient Investment Point - Chapter 225



Only Noblemtl

225. NASDAQ Hit Listing, and After – 2

(1)

After that, I was out of my mind.

I think I was interviewed by reporters from Korea and abroad, but they didn’t know what I was saying.

Anyway, the weight of the questions was much higher for Lee Seong-yong and Bae Jong-hyeon than for me, and later on, Lee Seong-yong received more questions than Bae Jong-hyeon, who gave short answers.

Of course, he also sighed as he returned to his accommodations after all the events were over.

“I have no idea what I said.”

“You spoke well, but what.”

“I came here after memorizing it all in advance. Hahaha.”

“There was no hint of it at all. Hahaha.”

This was the effect of the experience and confidence of a man named Lee Seong-yong.

In fact, to run a bio startup in Korea, the CEO must be good at speaking.

That makes sense, since over 90% of them are loss-making companies, what would it take to prove investment value?

All they could do was show their determination to hit the jackpot by providing a clear vision.

But usually developers are weak in that area.

Even in the case of Bae Jong-hyun, he only showed his pride in the beginning and was not able to express it properly.

Accordingly, Dr. Carty’s management gradually passed to Lee Seong-yong, who was a person who had a thorough understanding of the investment mechanism.

“I don’t know about anything else, but the fact that the 4th generation will develop the first anticancer drug for pancreatic cancer was the best.”

“That’s… I’m just saying. In reality, our ship’s representative does everything.”

As our gaze naturally shifts to Bae Jong-hyun, his face turns red.

“Oh, yes… … . I’ll just do my best.”

And since he repeated what he said at the press conference earlier, Lee Seong-yong and I had a good laugh.

This was also temporary, from this point on, Lee Seong-yong and I were busy receiving phone calls again.

How did they get our number? Because we were flooded with interview requests from foreign reporters again.

At least I was a Korean reporter… … ,

“Oh, sorry. We are going to Korea tomorrow.”

Lee Seong-yong continued to receive interview requests from local reporters.

It seems that the Q&A session we had today wasn’t enough.

This continued until we entered the accommodation, and didn’t stop until Liam Christopher came looking for us.

It would have been fine if they didn’t accept it, but Lee Seong-yong seemed to want to leave a good impression on them.

I had no choice but to talk to Liam.

“First of all, congratulations.”

“I should be the one who congratulates you.”

First of all, we exchanged congratulations.

Both JTS Partners and Flagship Pioneer were investors.

Of course, this time we were able to make a big exit, and the former was bound to be a bigger hit.

‘With a small investment, you can pull off a really big result… … .’

With its listing on NASDAQ, Dr. Carty’s market capitalization exceeded 52 trillion won.

Our stake was 15%, but it was diluted by half due to the issuance of new shares and sale of old shares.

In other words, I got my hands on a whopping 3.9 trillion won worth of shares, but I ‘exited’ about half of them, or 2 trillion won.

The total amount invested so far was approximately 20 billion won, so it was truly unprecedented.

Of course, the 2 trillion won did not go solely into JTS Partners’ account.

Half of the investment was made with our company’s assets, but the other half was raised from other investors through blind funds and other means.

So, once we get to Korea, our accounting team is going to be really busy.

The money needs to be transferred individually to the investor’s personal account…

“I was surprised that more investors’ money poured in than expected.”

“Yes, I felt the same way, but I think there was a reason.”

“Oh, is there a reason we don’t know about?”

“There’s something I didn’t tell you because I was worried you might worry.”

What is that?

Liam answered my questions right away.

“Chairman Jaden, this is a sabotage by Stephen Russell.”

“ah…….”

When the name of the chairman of an American big pharma company, which I had not heard in a long time, came out of his mouth, I nodded.

“I came here and read the newspaper too.”

Actually, I had read something after coming to the United States where Stephen Russell criticized Dr. Carty.

In summary, it was as follows.

1. Dr. Kati’s representative is a former head of the development team at Shinra Pharmaceuticals in Korea who stole preclinical stage technology and founded a startup.

2. Therefore, the original technology for the anticancer drug is in Korea’s Silla Pharmaceutical, and denying this and listing it on NASDAQ is no different from fraud.

3. Even though the legal battle is still ongoing, there is a very high chance that Shinra Pharmaceutical will win.

4. Investors should pay special attention to this as it may lead to delisting later.

If someone who doesn’t know reads this, it’s definitely something to take seriously.

But since Liam didn’t mention it specifically, the three of us didn’t bother asking.

“Stephen Russell is someone who can have a big influence on the pharmaceutical cartel in the United States. In fact, his words were accepted at first. So the NASDAQ listing was delayed a little bit, but later it helped a lot.”

“If it would be a big help… … .”

“Because that person kept talking so loudly, even strangers started paying attention.”

“ah…….”

It was a kind of noise marketing, and something similar happened in Korea.

People have become more aware of the anticancer drug Kartib thanks to the long-running lawsuit by Shinra Pharmaceutical against Dr. Karti.

“And in context, there is no criticism of Kartip, which means there is no denial of the possibility of clinical success.”

“Of course, Shilla Pharmaceutical is also attempting a similar clinical trial.”

“Yes. It’s a similar clinical trial, but I couldn’t disparage Kartip. That’s why I informed many institutional investors of this point during the IR before the demand forecast. The lawsuit is still ongoing, but Kartip itself has a very high chance of success. To the extent that Jaden wouldn’t go that far.”

“Wow, you did a good job. Hahaha.”

I laughed heartily again.

At the same time, I felt reassured by meeting a capable business partner.

‘Now I just need to succeed in Phase 2 B and Phase 3.’

Perhaps the road will be much more difficult and arduous than it has been so far.

But if I’m going to survive, I have to succeed somehow.

‘The probability has increased with this listing.’

Why? Because we were able to secure a huge amount of live ammunition.

I can already picture developing anticancer drugs.

Hoping that the day will come soon when I can extend my life to its fullest… … .

(2)

At that moment, Jayden’s chairman, Steven Russell, slammed his desk.

“Shit!”

Dr. Carty’s listing today was clearly an over-reflection of the market’s high expectations, but I still felt bad.

This hysteria prompted him to call Sung Hyun-woo, the CEO of Shinra Pharmaceuticals, on his smartphone.

– hello?

“I am coming.”

– Oh, Mr. Chairman. It’s been a while.

“Did you know that Dr. Katy went public today?”

Steven didn’t even offer a proper greeting and started talking about Dr. Carty right away.

Then a voice came from beyond the smartphone… … .

– Yes, I know.

“You know? No, then what are you doing?”

– What are you doing?

“Whether you win the lawsuit or get ahead in the clinical trial, you have to do one of them right!”

– … … .

That’s ridiculous.

Litigation doesn’t end that quickly and easily.

In particular, it was not easy to prove Bae Jong-hyun’s crimes because Dr. Katy had largely avoided key substances obtained during the preclinical stage at Shinra Pharmaceutical.

Even if you barely win the first trial, there are still the second and third trials left.

Steven knew that, but right now he needed someone to vent his anger on.

Fortunately, Sung Hyun-woo is the type to submit to Super Gap.

– I have no face.

“Ugh… … .”

If I had been angry, I would have poured more, but since he was lying face down like this, it was hard to get even angrier.

“How is the clinical trial going?”

– Phase 1 is on the verge of passing.

“What took so long?”

– Phew, the Ministry of Food and Drug Safety repeatedly rejected the application, saying the candidate substances were the same.

“No, you stole it from Dr. Carty first, so you’re not going to acknowledge the preclinical stage we originally dealt with?”

– That’s the law here…

This is also not unique to Korea.

In the United States, it is not the case that the first developer has priority, but rather the first to obtain a patent has a legal advantage.

Even though he knew everything, Stephen Russell lost his temper once again.

– So, we had no choice but to change the two candidate substances, and it seems that they will pass the clinical trial.

“What if I changed two of them? Is that okay?”

– Yes, since these were things discovered by the previous development team during the preclinical stage, there should be no problems at all. In fact, the research team said that this is much more stable than Kartip.

“More than Kartib? No, does that mean you won’t use Kartib?”

– Yes.

“… … .”

Stephen Russell’s eyebrows furrow.

Kartib is not the only candidate for the fourth-generation anticancer drug.

Kartip is the core, and the other four candidates were mixed to create a metabolic anticancer drug.

But they say they removed the key Kartip,

‘What, there are such idiots?’

Steven was speechless because he was so dumbfounded.

However, Sung Hyun-woo also had something to say.

– But you don’t have to worry. Originally, Kartib was the substance that Jong-Hyeon Bae replaced. In other words, when I was the team leader of our company, we were making metabolic anticancer drugs using other key substances, not Kartib.

“Oh, really?”

– Yes, but in order to prepare for a lawsuit later, we changed the core material to Kartib. For that reason, Phase 1 is the only problem, and Phases 2 and 3 are probably where we can secure a more stable relative advantage.

It’s a bluff. It’s just making a big statement without any basis. But Steven wanted to believe Sung Hyun-woo’s words.

“Okay, I understand. Well, I’ll wait for the good news.”

– Yes, Chairman. Oh, but… … .

“What now?”

– As we are trying to align the development team with the best researchers in the country, a lot of money is being invested. Furthermore, the stock price has plummeted as the phase 1 clinical trial is repeatedly rejected.

Seong Hyun-woo’s words were true.

Although we are not the best in the country, we have recruited many researchers with extensive clinical experience.

A lot of money was invested in building the latest facilities there.

Even if Shilla Pharmaceutical had a stable source of income, how could it support that much money at once?

– So, can you please invest additionally… … .

“Okay, I understand. I’ll contact you separately after the photo meeting.”

– thank you.

“Well then, I look forward to good news and I’ll hang up.”

Humans are animals that, after being greatly disappointed, begin to expect something again.

Otherwise, you can’t live with frustration.

The same goes for Stephen Russell.

I don’t know about anything else, but after I hung up the phone, I kept repeating one thing in my head.

‘Are Phase 2 and Phase 3 more stable than Kartip? Can they gain an advantage?’

Even if Sung Hyun-woo’s words were empty boasts, Steven was being forcibly hypnotized.

‘Yes, you can!’

More than ever, Steven was reluctant to tolerate Dr. Carty’s challenge.